A 12-month pilot study of Pacira BioScience’s iovera for chronic lower back pain showed it was favorable compared to compared to radiofrequency ablation, according to a Dec. 2 news release.
Researchers did a randomized, 30-patient study evaluating RFA and iovera and followed outcomes over 12 months. Iovera is a drug-free treatment designed to relieve pain through cryoneurolysis.
The unblinded, single-center study found that patients treated with iovera had “significantly lower” pain scores after 180 and 360 days compared to RFA patients. Functional disability in the iovera group improved more substantially compared to the RFA group.
There were no treatment-related adverse events reported in either group.
The study was published in Pain Physician.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
